Possible role of HSP60 in synergistic action of anthracyclines and sulindac in HeLa cells

Acta Poloniae Pharmaceutica - Drug Research

Volumn 67, Issue 6, 2010, Pages 620-624

  Gruber, Beata M ^a   Krzysztoń Russjan, Jolanta ^a   Bubko, Irena ^a   Anuszewska, Elzbieta L ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Apoptosis; Doxorubicin; HSF1; HSP60; Sulindac

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK TRANSCRIPTION FACTOR 1; MESSENGER RNA; SULINDAC;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG POTENTIATION; HELA CELL; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CHAPERONIN 60; CYTOSOL; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HELA CELLS; HUMANS; MITOCHONDRIA; PROTEIN TRANSPORT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULINDAC; TRANSCRIPTION FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 78049248593     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chandra D., Choy G., Tang D. G.: J. Biol. Chem. 282, 31289 (2007).
2. Xanthoudakis S., Roy S., Rasper D. et al.: EMBO J. 18, 2049 (1999).
3. Samali A., Cai J., Zhivotovsky B. et al.: EMBO J. 18, 2040 (1999).
4. Vilaboa N. E., Galan A., Troyanos A. et al.: J. Biol. Chem. 275), 24970 (2000).
5. Pope J. E., McCrea K., Stevens A. et al.: Med. Sci. Monit. 14, CR604 (2008).
6. Kang H.-K., Lee E., Pyo H., Lim S.-J.: Mol. Cancer Ther. 4, 1358 (2005).
7. Zalewska R., Zalewski B., Reszec J. et al.: Med. Sci. Monit. 14, BR274 (2008).
8. Baek S. J., Wilson L. C., Lee Ch.-H., Eling T E.: J. Pharmacol. Exp. Ther. 301, 1126 (2002).
9. Zhang T., Fields J. Z., Ehrlich S. M., Boman B. M.: J. Pharmacol. Exp. Ther. 308, 434 (2004).
10. Zatelli M. C., Luchin A., Piccin D. et al.: J. Clin. Endocrinol. Metab. 90, 5754 (2005).
11. O'Connor R., Heenan M., Connolly L., Larkin A., Clynes M.: Anticancer Res. 24, 457 (2004).
12. Puhlmann U., Ziemann Ch., Ruedell G., et al.: J. Pharmacol. Exp. Ther. 312, 346 (2005).
13. de Groot D. J., Timmer T., Spierings D. C., Le T. K. ,de Jong S., de Vries E. G.: Br. J. Cancer 92, 1459 (2005).
14. Gruber B. M., Bubko I., Krzysztoń-Russjan J., Anuszewska E. L.: Med. Sci. Monit. 16, BR45 (2010).
15. Livak K. J., Schmittgen T. D.: Methods 25, 402 (2001).
16. Bustin S. A.: J. Mol. Endocrinol. 25, 169 (2005).
17. Kirchhoff S. R., Gupta S., Knowlton A. A.: Circulation 105, 2899 (2002).
18. Shan Y-.X., Liu T.-J., Su H.-F. et al.: J. Mol. Cell Cardiol. 35, 1135 (2003).
19. Faried A., Sohda M., Nakajima M. et al.: Eur. J. Cancer 40, 2804 (2004).
20. Batulan Z., Nalbantoglu J., Durham H. D.: Cell Stress Chaperones 10, 185 (2005).